What does this research mean for the field?

In agitated COPD patients receiving noninvasive ventilation, dexmedetomidine significantly improves agitation control and reduces delirium compared to no sedation, but does not improve noninvasive ventilation success rates, ICU mortality, or length of stay. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of dexmedetomidine compared with conservative management without sedation for controlling agitation and avoiding invasive mechanical ventilation in COPD patients receiving noninvasive ventilation.

September 8, 2026Egyptian Journal of BronchologyOpen Access

Dexmedetomidine versus No-sedation for Agitation Control in COPD Patients receiving Noninvasive Ventilation: a Randomized Trial

View Full Paper

Ask AI

Bookmark

Authors

OEOlfat M. El-Shinnawy HSHend M. Sayed HAHoda S. Ahmed

Discussion

Member takes

Overview

Randomized trial reveals dexmedetomidine improves agitation control in agitated COPD patients on noninvasive ventilation, suggesting sedative benefits without altering ventilation success.

Key Points

To evaluate the efficacy and safety of dexmedetomidine compared with conservative management without sedation for controlling agitation and avoiding invasive mechanical ventilation in COPD patients receiving noninvasive ventilation.
Randomized controlled trial enrolling 93 agitated COPD patients (Richmond Agitation-Sedation Scale [RASS] ≥ +2) receiving noninvasive ventilation (NIV), with 80 analyzed.
Participants were assigned to receive either conservative management alone (n=41) or IV dexmedetomidine infusion at 0.2–0.7 mcg/kg/h (n=39).
Assessed sedation using RASS, vital signs, arterial blood gases, delirium, and noninvasive ventilation outcomes over 48 hours.
Agitation control (RASS 0 to -2 at 48 hours) was significantly higher with dexmedetomidine than with no sedation (81.2% vs. 34.1%, P < 0.001), and delirium occurred less frequently (1 vs. 8 patients, P = 0.029).
No significant differences occurred between groups for NIV success (P = 0.328), NIV duration (P = 0.086), ICU mortality (P = 0.999), or ICU length of stay (P = 0.817).
Diastolic blood pressure was significantly lower at 12 and 24 hours in the dexmedetomidine group, while heart rate and systolic blood pressure remained comparable.

Cite This Study

El-Shinnawy et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd79b58e84d0ff5b4658d https://doi.org/10.1186/s43168-026-00659-4

View Full Paper

Ask AI

Bookmark

September 8, 2026Egyptian Journal of BronchologyOpen Access

Dexmedetomidine versus No-sedation for Agitation Control in COPD Patients receiving Noninvasive Ventilation: a Randomized Trial

View Full Paper

Ask AI

Bookmark

Authors

OEOlfat M. El-Shinnawy HSHend M. Sayed HAHoda S. Ahmed

Discussion

Member takes

Overview

Randomized trial reveals dexmedetomidine improves agitation control in agitated COPD patients on noninvasive ventilation, suggesting sedative benefits without altering ventilation success.

Key Points

To evaluate the efficacy and safety of dexmedetomidine compared with conservative management without sedation for controlling agitation and avoiding invasive mechanical ventilation in COPD patients receiving noninvasive ventilation.
Randomized controlled trial enrolling 93 agitated COPD patients (Richmond Agitation-Sedation Scale [RASS] ≥ +2) receiving noninvasive ventilation (NIV), with 80 analyzed.
Participants were assigned to receive either conservative management alone (n=41) or IV dexmedetomidine infusion at 0.2–0.7 mcg/kg/h (n=39).
Assessed sedation using RASS, vital signs, arterial blood gases, delirium, and noninvasive ventilation outcomes over 48 hours.
Agitation control (RASS 0 to -2 at 48 hours) was significantly higher with dexmedetomidine than with no sedation (81.2% vs. 34.1%, P < 0.001), and delirium occurred less frequently (1 vs. 8 patients, P = 0.029).
No significant differences occurred between groups for NIV success (P = 0.328), NIV duration (P = 0.086), ICU mortality (P = 0.999), or ICU length of stay (P = 0.817).
Diastolic blood pressure was significantly lower at 12 and 24 hours in the dexmedetomidine group, while heart rate and systolic blood pressure remained comparable.

Cite This Study

El-Shinnawy et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd79b58e84d0ff5b4658d https://doi.org/10.1186/s43168-026-00659-4

View Full Paper

Ask AI

Bookmark